Lupus & antiphospholipid syndrome
Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus
Authors' conclusion
RONT, ROFT and LLDAS were associated with significant and clinically relevant higher QoL in most PRO domains of the LupusPRO (disease specific) and SF-36 (generic) questionnaires, but not with LupusQoL and SLEQOL disease-specific questionnaires.
Study context
- Population
- Patients with SLE
- Participants
- 336 patients1,478 visits
- Exposure
- Remission off treatment (ROFT) and remission on treatment (RONT) vs no remission; Lupus low disease activity state (LLDAS) vs no LLDAS
- Outcome
- Association between SLE remission and patients-reported outcome (PRO) scores (LupusPRO, LupusQoL, SLEQOL, SF-36)
Methodological details2-year follow-up, mixed models accounting for repeated measures
- 2-year follow-up
- Mixed models accounting for repeated measures
Main finding
As reported in the abstract
Between-group difference in PRO scores of at least 5 points (0-100 scale)
- Lupus Patient-Reported Outcome (LupusPRO) lupus symptoms: LLDAS
- +5
- LupusPRO lupus symptoms: RONT
- +9
- LupusPRO lupus symptoms: ROFT
- +5
- LupusPRO lupus medication: LLDAS
- +5
- LupusPRO lupus medication: RONT
- +8
- LupusPRO lupus medication: ROFT
- +9
- LupusPRO pain vitality: LLDAS
- +6
- LupusPRO pain vitality: RONT
- +9
- LupusPRO pain vitality: ROFT
- +6
- Short Form (SF-36) role emotional: LLDAS
- +5
- SF-36 role emotional: RONT
- +8
- SF-36 role physical: RONT
- +7
- SF-36 role physical: ROFT
- +7
- SF-36 bodily pain: RONT
- +6
- SF-36 mental health: RONT
- +5
- SF-36 social functioning: RONT
- +6
Observational data: associations, not effects.
Original publication
Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus. Rheumatology (Oxford). Published 17 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →